Discovered and developed by Centocor, ustekinumab (CNTO 1275) is an investigational MAb with a novel dual mechanism of action. Its initial indication is for the treatment of moderate to severe plaque psoriasis.
-
Discovered and developed by Centocor, ustekinumab (CNTO 1275) is an... -
Studies conducted to date suggest that ustekinumab is an effective treatment... -
A variety of tools have been used to assess the severity of plaque psoriasis...
